武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TAK 武田制药

交易中 07-22 10:30:24 EDT

13.51

+0.15

+1.12%

最高13.57	最低13.41	成交量31.47万
今开13.41	昨收13.36	日振幅1.16%
总市值428.23亿	流通市值423.04亿	总股本31.70亿
成交额425.57万	换手率0.01%	流通股本31.31亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"武田制药","latestPrice":13.51,"timestamp":1721658621584,"preClose":13.36,"halted":0,"volume":314683,"delay":0,"floatShares":3131342522,"shares":3169718944,"eps":0.301345,"marketStatus":"交易中","marketStatusCode":2,"change":0.15,"latestTime":"07-22 10:30:24 EDT","open":13.41,"high":13.565,"low":13.41,"amount":4255708.381985,"amplitude":0.011602,"askPrice":13.52,"askSize":2500,"bidPrice":13.51,"bidSize":1335,"shortable":3,"etf":0,"ttmEps":0.301345,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"listingDate":1545627600000,"adjPreClose":13.36,"adrRate":0.5,"dividendRate":0.044391,"preHourTrading":{"tag":"盘前","latestPrice":13.41,"preClose":13.36,"latestTime":"09:29 EDT","volume":449,"amount":6023.629544,"timestamp":1721654993070},"postHourTrading":{"tag":"盘后","latestPrice":13.36,"preClose":13.36,"latestTime":"18:47 EDT","volume":122105,"amount":1633355.33,"timestamp":1721429249355},"volumeRatio":0.689554,"impliedVol":0.3887,"impliedVolPercentile":0.8845},"requestUrl":"/m/hq/s/TAK","defaultTab":"news","newsList":[{"id":"2445093946","title":"和黄医药：武田获得欧盟委员会批准FRUZAQLA (呋喹替尼)","url":"https://stock-news.laohu8.com/highlight/detail?id=2445093946","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445093946?lang=zh_cn&edition=full","pubTime":"2024-06-24 08:14","pubTimestamp":1719188066,"startTime":"0","endTime":"0","summary":"和黄医药发布公告，该公司今日宣布其合作伙伴武田取得欧盟委员会批准FRUZAQLA 作为单药疗法用于治疗既往接受过包括氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗、抗血管内皮生长因子治疗以及抗表皮生长因子受体治疗在内的现有标准治疗，以及曲氟尿苷替匹嘧啶或瑞戈非尼治疗后疾病进展或不耐受的成人转移性结直肠癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062408455895d06a4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062408455895d06a4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4588","HCM","TAK","BK4585","BK4531"],"gpt_icon":0},{"id":"2445470157","title":"上海原创新药首次登陆美欧市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2445470157","media":"解放日报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445470157?lang=zh_cn&edition=full","pubTime":"2024-06-23 05:29","pubTimestamp":1719091747,"startTime":"0","endTime":"0","summary":"由此，呋喹替尼成为上海首个成功出海美国、欧洲两大标杆市场的原创新药。去年11月，呋喹替尼在美国获批后48小时内，即开出首张处方。根据武田制药公布的数据，呋喹替尼在美国市场2024年第一季度的销售额已超5000万美元。据悉，呋喹替尼在日本等多个国家和地区的上市申请正在积极推进中，呋喹替尼二线治疗胃癌以及联合信迪利单抗用于治疗晚期子宫内膜癌的中国新药上市申请已进入国家药监局审评环节。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062305291095cd7670&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062305291095cd7670&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK4007","HCM","BK4588","BK4531","BK4585","TAK"],"gpt_icon":0},{"id":"2444589982","title":"拆解国产小分子BD第一案","url":"https://stock-news.laohu8.com/highlight/detail?id=2444589982","media":"钛媒体APP","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444589982?lang=zh_cn&edition=full","pubTime":"2024-06-20 11:27","pubTimestamp":1718854032,"startTime":"0","endTime":"0","summary":"总计13亿美元的金额，创下了国产小分子药物对外BD的新纪录。这可能预示着国产小分子药物的崛起。这也表明，亚盛医药此前被市场质疑的流动性危机已经彻底解除。尽管亚盛医药的临床数据和BD交易条款已经证明了耐立克的价值，但武田制药成为其重要股东，更是进一步证实了耐立克的价值。把对手变为队友背后亚盛医药此次BD的另一大亮点，是合作伙伴武田制药本身。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201131489f50ccef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201131489f50ccef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","TAK","BK1515","BK1574","06855"],"gpt_icon":0},{"id":"2444129476","title":"13亿美元BD交易验证耐立克®全球商业化潜力，亚盛医药-B(06855)踏上估值跃迁关键期","url":"https://stock-news.laohu8.com/highlight/detail?id=2444129476","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444129476?lang=zh_cn&edition=full","pubTime":"2024-06-18 11:07","pubTimestamp":1718680066,"startTime":"0","endTime":"0","summary":"6月14日，亚盛医药盘后连发三则公告引发业界和市场的广泛关注。强强联合，开启国际商业化新纪元对于投资者而言，若想对亚盛医药和武田制药此次13亿美元BD交易与合作有充分理解，就需要从耐立克的全球开发与商业化及股权投资这两大亮点内容入手。武田制药看中耐立克的主要原因在于该药商业化价值已获国内市场阶段性验证，而其治疗与全球商业化潜力仍有不断被深掘的巨大价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181112319f489b75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181112319f489b75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","06855","TAK","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2444294241","title":"武田(TAK.US)同类首创CH24H抑制剂错失2项III期研究主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2444294241","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444294241?lang=zh_cn&edition=full","pubTime":"2024-06-18 11:04","pubTimestamp":1718679867,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月17日，武田和Ovid Therapeutics共同公布了soticlestat治疗癫痫的两项III期SKYLINE和SKYWAY研究的初步数据。SKYLINE研究旨在评估soticlestat+标准治疗相较于安慰剂+标准治疗在Dravet综合征患者中的疗效。与安慰剂相比，soticlestat错过了惊厥性癫痫发作频率的主要终点。资料显示，Soticlestat是一款潜在first-in-class的CH24H抑制剂，CH24H是一种主要在大脑中表达的酶，可将胆固醇分解为24-S羟基胆固醇，从而降低谷氨酸能过度兴奋性。武田将与监管机构讨论这些研究产生的全部数据，以确定下一步措施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","III","BK4134","TAK"],"gpt_icon":0},{"id":"2437727904","title":"达歌生物与武田制药携手开发新型分子胶降解剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2437727904","media":"环球网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437727904?lang=zh_cn&edition=full","pubTime":"2024-05-24 11:06","pubTimestamp":1716520009,"startTime":"0","endTime":"0","summary":"此次与武田制药的合作，达歌生物将利用其强大的研发能力，为武田选定的特定疾病靶点发现、验证并优化分子胶降解剂。一旦项目达到一定进展阶段，武田制药将接手进行后续的开发和商业化工作。武田制药方面表示，分子胶降解剂作为一种新型药物，具有靶向传统手段难以触及的疾病靶点的潜力。此次与达歌生物的合作，将为武田制药的药物研发领域注入新的创新活力，有望为全球患者带来更多突破性的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524110752aef17727&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524110752aef17727&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2436946893","title":"武田制药2024财年实现净利润9.96亿美元，同比减少57.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436946893","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436946893?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:21","pubTimestamp":1715962915,"startTime":"0","endTime":"0","summary":"3月31日，武田制药公布财报，公告显示公司2024财年净利润为9.96亿美元，同比减少57.42%；其中营业收入为294.86亿美元，同比减少0.78%，每股基本收益为0.32美元。机构评级：截至2024年3月31日，当前有12家机构对武田制药目标价做出预测，其中目标均价为15.85美元，其中最低目标价为13.47美元，最高目标价为20.00美元。公司简介：武田药品是日本最大的制药公司，2022财年营收为4万亿日元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180022058b131b34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180022058b131b34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK"],"gpt_icon":0},{"id":"2435630956","title":"武田(TAK.US)TYK2抑制剂在华启动银屑病3期临床 全球计划招募1600人","url":"https://stock-news.laohu8.com/highlight/detail?id=2435630956","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435630956?lang=zh_cn&edition=full","pubTime":"2024-05-15 21:00","pubTimestamp":1715778055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，中国药物临床试验登记与信息公示平台公示，武田启动了TAK-279片的两项国际多中心(含中国)3期临床研究，针对适应症为中重度斑块状银屑病。公开资料显示，TAK-279是一款高选择性、口服别构酪氨酸激酶2抑制剂。据了解，除了武田的TAK-279片，全球还有不少TYK2抑制剂正在开发或已经在银屑病的治疗中取得突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2435320698","title":"武田制药(TAK.US)引进AC Immune阿尔茨海默症Aβ疫苗疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2435320698","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435320698?lang=zh_cn&edition=full","pubTime":"2024-05-13 21:07","pubTimestamp":1715605667,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月13日，武田制药(TAK.US)宣布引进AC Immune的阿尔茨海默症Aβ疫苗疗法ACI-24.060，武田支付1亿美元预付款，约21亿美元里程碑金额，以及中至高十位数的销售分成。据悉，ACI-24.060为一款Aβ疫苗，诱导产生Aβ抗体，以及Th细胞响应，目前处于二期临床阶段。目前阿尔茨海默症获批的新疗法主要是Aβ抗体，而AC Immune的技术路线是Aβ疫苗，注射后可以诱导抗体免疫和细胞免疫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK4135","TAK","AC","BK4007"],"gpt_icon":0},{"id":"2434016556","title":"武田制药2023财年净利润同比下降超54% 宣布重组计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2434016556","media":"新浪财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434016556?lang=zh_cn&edition=full","pubTime":"2024-05-09 22:12","pubTimestamp":1715263972,"startTime":"0","endTime":"0","summary":"格隆汇5月9日｜日本武田制药公布2023财年全年业绩，营收为42638亿日元，同比增长5.9%；净利润为1441亿日元，同比下降54.6%；非公认会计准则每股收益为484日元，同比下降13.4%。该公司表示，将在2024财年承担1400亿日元的一次性重组成本。该公司宣布将启动一项多年期计划，根据该计划，武田将优化员工队伍，并投资于技术和数据，以将核心营业利润率提高30%以上。此举将使武田能够“为患者创造更多的长期价值”。股市回暖，抄底炒股先开户！","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-05-09/doc-inaurxyf2717961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["TAK"],"gpt_icon":0},{"id":"2434065781","title":"武田制药(TAK.US)2023财年净利润同比降低54.6% 将进行1400亿日元重组以提高利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2434065781","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434065781?lang=zh_cn&edition=full","pubTime":"2024-05-09 16:53","pubTimestamp":1715244780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，武田制药(TAK.US)公布了2023财年全年业绩，财报显示，武田制药全财年营收为42638亿日元，同比增长5.9%；净利润为1441亿日元，同比降低54.6%；非公认会计准则每股收益为 484 日元，同比降低13.4%。该公司表示，将在2024财年承担1400亿日元(合9亿美元)的一次性重组成本，该公司将启动一项多年期计划，以提高利润率。武田在周四的一份声明中表示，根据该计划，武田将优化员工队伍，并投资于技术和数据，以将核心营业利润率提高30%以上。声明称，此举将使武田能够“为患者创造更多的长期价值”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK"],"gpt_icon":0},{"id":"2434105193","title":"Takeda Pharmaceutical(TAK.US)：2023年Q4财报实现营收70.82亿美元，前值为72.29亿美元；每股收益为0.24美元，前值为0.39美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434105193","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434105193?lang=zh_cn&edition=full","pubTime":"2024-05-09 14:55","pubTimestamp":1715237747,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical(TAK.US)：2023年Q4财报实现营收70.82亿美元，前值为72.29亿美元；每股收益为0.24美元，前值为0.39美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050914554987e373a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050914554987e373a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK"],"gpt_icon":0},{"id":"2422543608","title":"武田制药总裁：创新为中国医疗健康行业赋予新质生产力","url":"https://stock-news.laohu8.com/highlight/detail?id=2422543608","media":"市场资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2422543608?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:48","pubTimestamp":1711374491,"startTime":"0","endTime":"0","summary":"专题：中国发展高层论坛2024年年会来源：CGTN【#先声夺人# |武田制药总裁：创新为中国医疗健康行业赋予新质生产力】3月24日，在中国发展高层论坛2024年年会现场，武田制药总裁卫博科接受CGTN主持人@田薇_TianWei专访。他表示，以大数据疾病诊疗为代表的先进科技的进步将进一步赋能医疗健康领域。在医药领域，实现制药技术与产品的进出口流动较为困难，武田制药将力促进中国制药进一步走向全球。新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252148188b6144da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252148188b6144da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"gpt_icon":0},{"id":"2422554249","title":"武田制药总裁、首席执行官卫博科：应该继续加大医疗卫生方面的预算","url":"https://stock-news.laohu8.com/highlight/detail?id=2422554249","media":"中国新闻网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2422554249?lang=zh_cn&edition=full","pubTime":"2024-03-25 13:56","pubTimestamp":1711346218,"startTime":"0","endTime":"0","summary":"中新网3月25日电中国发展高层论坛2024年年会于2024年3月24-25日举行。在3月24日下午举行了“大健康产业专题研讨会”，武田制药总裁、首席执行官卫博科在“小组讨论一”环节的发言中表示：应该继续加大医疗卫生方面的预算。卫博科就大健康在中国的发展分享了三点想法：一是不断创新。创新可以为保护健康带来更多的机会，也可以让医疗更好地触及患者。这需要更加完善的批准和报销体系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403253022734920.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403253022734920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BRCD","TAK","BK4007"],"gpt_icon":0},{"id":"2419279615","title":"丰田汽车(TM.US)超越武田制药(TAK.US) 成亚太区最大做空股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419279615","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419279615?lang=zh_cn&edition=full","pubTime":"2024-03-13 14:46","pubTimestamp":1710312411,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据财资管理及证券融资平台Hazeltree周二发布的报告显示，汽车制造商丰田汽车超过武田制药，在二月份成为亚太地区对冲基金做空最多的大型股票。做空交易是押注一家公司的股价下跌。此外，该报告还指出，美国电动汽车制造商特斯拉仍是美洲被做空最多的股票，而奢侈品集团LVMH 连续第六个月成为欧洲、中东和非洲地区的首位。在中型股票方面，列车制造商阿尔斯通和芯片制造商Wolfspeed分别继续是EMEA和美洲地区最受做空的股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1085834.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","BK4585","TM","03160","BK4007","BK4555","BK4099"],"gpt_icon":0},{"id":"2415259968","title":"百度健康上线罕见病中心，法布雷病及HAE患者可开展线上自筛","url":"https://stock-news.laohu8.com/highlight/detail?id=2415259968","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415259968?lang=zh_cn&edition=full","pubTime":"2024-02-29 16:11","pubTimestamp":1709194260,"startTime":"0","endTime":"0","summary":"由健康管理平台百度健康携手中国罕见病联盟共建的\"罕见病中心\"正式升级上线。在我国，法布雷病的总体筛查诊断率仅为3%。延迟诊断会增加HAE患者因喉部水肿发作导致的死亡风险。此次百度健康上线\"罕见病中心\"将为这些疾病提供科普和自筛指引，一方面提升大众对于法布雷病及HAE的疾病认知，另一方面帮助公众在面对疾病威胁时能够做到\"早筛查、早发现，早治疗\"，从而提高诊断意识。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4349121_ZH49121_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0640798160.USD","LU1169589451.USD","BIDU","BK4585","LU1169590202.USD","HAE","BK4007","TAK","BK4198","BK4504","BK4531","BK4588","IE00B64QTZ34.USD","BK4587","BK4535","LU1023057109.AUD","BK4579","LU0287142896.SGD","LU0359202008.SGD","IE00B0JY6N72.USD","BK4548","LU1115378108.SGD","BK4552","LU0173614495.USD","BK4574","BK4514","BK4526","BK4077","LU0359201612.USD"],"gpt_icon":0},{"id":"2409834794","title":"全新机制抗病毒药物马立巴韦片开出全国首处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2409834794","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409834794?lang=zh_cn&edition=full","pubTime":"2024-02-08 18:44","pubTimestamp":1707389040,"startTime":"0","endTime":"0","summary":"马立巴韦的出现，让我们临床医生有了新的武器来应对移植后的CMV反复感染。期待患者在接受马立巴韦后，能够有良好的预后。作为创新靶向药物，马立巴韦可高效清除CMV血症并控制相关症状，且治疗限制性毒性更低。同时，马立巴韦片与常规抗病毒治疗相比，治疗限制性毒性更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4332493_ZH32493_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4196","IE00B19Z3B42.SGD","TAK","IE00B19Z3581.USD","BK4007","IE00BSNM7G36.USD","BK4201","EC","IE0002270589.USD","BK4585","LU0058720904.USD","CI","LU0289739699.SGD","BK4588","LU0868494617.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.takeda.com","stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0545},{"period":"3month","weight":0.0091},{"period":"6month","weight":-0.0918},{"period":"1year","weight":-0.1296},{"period":"ytd","weight":-0.0638}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Takeda Pharmaceutical Company Limited是一家在日本注册成立的上市公司成立于1925年1月12日。该公司及其子公司是一家主要的全球制药集团，从事医药产品、非处方药和准药品消费品以及其他医疗保健产品的研究、开发、制造和营销。武田的主要医药产品包括以下治疗领域的药物：胃肠病学、肿瘤学和神经科学。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.03791},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.021005},{"month":3,"riseRate":0.5,"avgChangeRate":-0.007765},{"month":4,"riseRate":0.5,"avgChangeRate":-0.007082},{"month":5,"riseRate":0.5,"avgChangeRate":0.000857},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.019551},{"month":7,"riseRate":0.5,"avgChangeRate":0.005702},{"month":8,"riseRate":0.6,"avgChangeRate":-0.012751},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01721},{"month":10,"riseRate":0.4,"avgChangeRate":-0.067649},{"month":11,"riseRate":0.8,"avgChangeRate":0.079016},{"month":12,"riseRate":0.8,"avgChangeRate":0.016238}],"exchange":"NYSE","name":"武田制药","nameEN":"Takeda Pharmaceutical Co Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"武田制药,TAK,武田制药股票,武田制药股票老虎,武田制药股票老虎国际,武田制药行情,武田制药股票行情,武田制药股价,武田制药股市,武田制药股票价格,武田制药股票交易,武田制药股票购买,武田制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}